Zentiva Snaps Up Alvogen’s CEE Operations
Alvogen To Focus On Asia And Alvotech’s Biosimilars
Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.
You may also be interested in...
Alvogen has struck a licensing deal with Yas Holding that gives the firm exclusive distribution rights to a portfolio of 28 generics in the Middle East and North Africa region from 2020.
With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.